Compare AbCellera Biologics Inc (ABCL) vs Tapestry, Inc. (TPR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Tapestry, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while Tapestry, Inc. trades at $141.16 (market cap $29.40B). The key difference: Tapestry, Inc. is far larger — about 12.5× AbCellera Biologics Inc's market cap, and Tapestry, Inc. pays a 1.1% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | TPR | |
|---|---|---|
Market Cap | $2.35B | $29.40B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $160.49 |
52-Week Low | $2.78 | $92.20 |
Enterprise Value | $1.99B | $32.25B |
Dividend Yield | — | 1.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
TPR trades at $146.3, up 1.45% today, with a bullish technical signal and strong analyst support. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $1.66 exceeding the $1.30 estimate. The company maintains high profitability margins, including a 76.18% gross margin and 55.74% ROE, though net income margin declined to 8.44% in 2025. Positive news highlights digital growth and Gen Z engagement, with a consensus price target of $184.14 implying significant upside.
Outlook is positive given earnings momentum and analyst optimism, but risks include high debt levels, volatile cash flows, and competitive pressures in the luxury retail sector. The stock's elevated P/E of 44.36 requires sustained growth to justify valuation, while institutional ownership trends and insider activity should be monitored for confirmation of bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
